A number of large clinical trials have convincingly demonstrated that SGLT2 inhibitors improve cardiovascular outcomes in T2DM patients, including a reduced risk of cardiovascular death and hospitalization for heart failure [37,38,39,40]. This evidence concerns the gene SLC5A2 and heart failure.